Initial response to salvage therapy determines prognosis in relapsed pediatric hodgkin lymphoma patients

Cancer

Volumn 116, Issue 18, 2010, Pages 4376-4384

  Metzger, Monika L ^a,b   Hudson, Melissa M ^a,b   Krasin, Matthew J ^a   Wu, Jianrong ^a   Kaste, Sue C ^a,b   Kun, Larry E ^a   Sandlund, John T ^a,b   Howard, Scott C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hodgkin lymphoma; Pediatric; Salvage therapy; Treatment failure

Indexed keywords

BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; NAVELBINE; PREDNISONE; PROCARBAZINE; TOPOTECAN; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SALVAGE THERAPY; TREATMENT FAILURE; ADOLESCENT; ADULT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 77957346788     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25225     Document Type: Article

References (37)

1. Hodgson DC, Hudson MM, Constine LS. Pediatric Hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230-242.
2. Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the Pediatric DAL/GPOH-HD Study Group. J Clin Oncol. 2005;23:6181-6189.
3. Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol. 2006;29:189-195.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339:1506-1514.
5. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026-2033.
6. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2002;20:221-230.
7. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081-3087.
8. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22:4541-4550.
9. Hudson M, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent (COP/ABVD) chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 1993;11:100-108.
10. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-637.
11. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
12. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood. 1993;81:1137-1145.
15. Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17:3101-3109.
16. Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998;9:289-295.
17. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96:1280-1286.
18. Rapoport AP, Rowe JM, Kouides PA, et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993;11:2351-2361.
19. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130:363-372.
20. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1065-1072.
21. Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002;13(suppl 1):112-116.
22. Lieskovsky YC, Torres M, Wong R, Agarwal R, Amylon M, Donaldson S. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Int J Radiat Oncol Biol Phys. 2003;57(suppl):S198-S198.
23. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol. 2004;22:4532-4540.
24. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26:740-745.
25. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065-2071.
26. Chopra R, Linch DC, McMillan AK, et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol. 1992;81:197-202.
27. Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704-711.
28. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
29. Lancet JE, Rapoport AP, Brasacchio R, et al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1998;22:265-271.
30. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795-800.
31. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-481.
32. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/ CT after first-line therapy - is biopsy of FDG-avid lesions still needed? Radiology. 2007;244:257-262.
33. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34:60-67.
34. Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica. 2006;91:482-489.
35. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol. 2006;85:759-767.
36. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after 2 courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-481.
37. Hutchings M, Loft A, Hansen M, et al. FDG-PET after 2 cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.